Diphtheria (DBCOND0000394)

Identifiers

Synonyms
Corynebacterium diphtheriae infection / Infection due to Corynebacterium diphtheriae (disorder) / Diphtheria caused by Corynebacterium diphtheriae (disorder) / Diphtheria, unspecified

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Benzylpenicillin
A penicillin used for the treatment of infections caused by gram-positive cocci, in particular streptococcal infections. This form of penicillin is typically used in intravenous or long-acting injectable formulations due to poor oral absorption.
Bordetella pertussis pertactin antigen (formaldehyde inactivated)
Not Annotated
No drug targets
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
Not Annotated
No drug targets
Clostridium tetani toxoid antigen (formaldehyde inactivated)
Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention...
No drug targets
Corynebacterium diphtheriae
Corynebacterium diphtheriae toxin is extracted from the pathogenic actinobacterium C. diphtheriae that causes diphtheria. The bacteria culture is grown in a medium and through purification, diphtheria toxin is detoxified with...
No drug targets
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
Not Annotated
No drug targets
Erythromycin
A macrolide antibiotic used to treat and prevent a variety of bacterial infections.
Procaine benzylpenicillin
A local anesthetic and antibiotic combination for intramuscular injection to treat a variety of bacterial infections while reducing pain from a deep intramuscular injection.
No drug targets
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06618196
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of AgeNo drug interventionsprevention2not_yet_recruiting
NCT06605755
Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old InfantsNo drug interventionspreventionNot Availablerecruiting
NCT06588530
PFAS Exposure and Immune Response to Vaccination in Adultsbasic_science4not_yet_recruiting
NCT01031303
Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Ageprevention4completed
NCT02422264
Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryprevention4completed
NCT00355121
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®prevention2completed
NCT00343421
Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and Toddlersprevention3completed
NCT00255021
Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailandprevention4completed
NCT00619502
Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish InfantsNo drug interventionsprevention3completed
NCT01248884
Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)prevention2completed
NCT02569879
Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks of Age, in Bogota, Colombia.No drug interventionsNot AvailableNot Availablecompleted
NCT01470287
Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 Weeks of AgeNo drug interventionsprevention3completed
NCT01491087
Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in Chinaprevention4completed
NCT00534833
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix-HepB/Hib™prevention3completed
NCT02094833
DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infantsprevention3completed
NCT02817451
DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infantsprevention3completed
NCT00319553
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®prevention4completed
NCT01738477
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young Adultsprevention3completed
NCT01062477
A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy Infantsprevention3completed
NCT00255047
Safety and Immune Response of Different Pediatric Combination Vaccines.prevention3completed
NCT00316147
Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Schedulesprevention3completed
NCT00168545
Immunology of Non-specific Effects of Vaccinediagnostic4completed
NCT02257645
Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 WeeksNo drug interventionsNot AvailableNot Availableunknown_status
NCT01294605
Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV)prevention4completed
NCT01277705
Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactivated Poliovirus Vaccine, to BoostrixTM and Inactivated Poliovirus Vaccine Administered Separately and With Revaxis®prevention3completed
NCT01249183
Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, Pertussis and Poliomyelitis Vaccine (REPEVAX) and Influenza Vaccine (VAXIGRIP) in Subjects Aged From 60 Years Oldprevention3completed
NCT02458183
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruSNo drug interventionsprevention3completed
NCT03870061
Evaluation of an Infant Immunization Encouragement Program in NigeriaNo drug interventionspreventionNot Availablecompleted
NCT02118961
Study of BK1301 (DTaP Vaccine) as a Booster in Adolescentsprevention3completed
NCT00337428
Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diptheria, Tetanus, Pertussis and Poliomyelitis Vaccine in Adolescents (V501-024)(COMPLETED)No drug interventionsprevention3completed
NCT00964028
Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib)prevention3completed
NCT04056728
A Phase IV Study to Assess the Safety of EupentaTM InjNo drug interventionsprevention4unknown_status
NCT00635128
Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccineprevention4completed
NCT00544271
Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccines.prevention4terminated
NCT01546909
Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRENo drug interventionsprevention4completed
NCT02274285
DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese InfantsNo drug interventionsprevention3completed
NCT04535037
A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlersprevention4completed
NCT00835237
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.prevention3completed
NCT00524732
Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of AgeNot AvailableNot Availablecompleted
NCT00319852
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPVprevention3completed
NCT01040052
A Study to Assess the Safety of Adacel® Vaccineprevention3completed
NCT00712959
Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Doseprevention4completed
NCT00611559
Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Childrenprevention4completed
NCT04073459
Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy InfantsNo drug interventionsprevention2unknown_status
NCT01323959
Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted AdultsNo drug interventionsprevention4completed
NCT00453570
Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Monthsprevention3completed
NCT00662870
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccineprevention3completed
NCT00432042
Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035)prevention3completed
NCT06184542
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccineprevention1recruiting
NCT00290342
Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infantsprevention3completed
NCT00457249
A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Olderprevention4completed
NCT00753649
Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infantsprevention4completed
NCT02040636
Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Poliomyelitisprevention2completed
NCT00467519
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Ageprevention3completed
NCT00871741
Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months of Age.prevention2terminated
NCT00228917
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Childrenprevention3completed
NCT00303316
Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentinean Infantsprevention3completed
NCT01659996
Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Ageprevention4completed
NCT01267058
Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adultsprevention3completed
NCT00347958
Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccineprevention4completed
NCT03891758
Confirmatory Study of BK1310 in Healthy Infantsprevention3completed
NCT00601835
Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Tdprevention4completed
NCT00146835
Post-marketing Safety Study of GSK Biological's Pediarix™ VaccineNot AvailableNot Availablecompleted
NCT00320463
Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Healthy Infantsprevention3completed
NCT00352963
Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age).No drug interventionsprevention3completed
NCT00452686
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccineprevention3completed
NCT04618939
To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy ChildrenNo drug interventionsprevention3completed
NCT03931239
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 WeeksNo drug interventionspreventionNot Availablecompleted
NCT01177722
A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infantsprevention3completed
NCT01362322
Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescentsprevention4completed
NCT01358825
Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/Hib™No drug interventionsprevention4completed
NCT00447525
REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Childrenprevention3completed
NCT00707148
Pertussis Vaccine in Healthy Pregnant Womenprevention1completed
NCT01311557
Study of Adacel® Vaccine Administered to Persons 10 Years of Ageprevention4completed
NCT00777257
Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccineprevention4completed
NCT01988857
Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Childrenprevention3completed
NCT00332566
Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTPw-HBV/Hibprevention3completed
NCT00304265
Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis VaccineNo drug interventionsprevention4completed
NCT01357720
Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood VaccinationNo drug interventionsprevention4completed
NCT04061382
Sero-epidemiological Survey of England in 2019/2020 - COVID-19No drug interventionsNot AvailableNot Availableunknown_status
NCT00401531
Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infantsprevention3completed
NCT00346073
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Yearsprevention3completed
NCT00879827
Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infantsprevention3completed
NCT01933776
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in Chinaprevention1completed
NCT01568060
Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in KoreaNo drug interventionsNot AvailableNot Availablecompleted
NCT05480462
Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria.No drug interventionsprevention3active_not_recruiting
NCT00316680
Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 Mths.Age.prevention3terminated
NCT03128489
Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at 6, 10 and 14 Weeks in Healthy Indian Infantsprevention3withdrawn
NCT01171989
Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster Doseprevention2completed
NCT01629589
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescentsprevention4completed
NCT00343889
Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio Vaccineprevention3completed
NCT00287092
Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule in Infantsprevention3completed
NCT02858440
A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a Three-dose Vaccination Course at 3, 4.5 and 6 Months of Age and a Booster Dose at 18 Months of Age in Healthy Infants in Russiaprevention3completed
NCT00802867
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™prevention4completed
NCT00291967
Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of Hib-MenAC Vaccine to InfantsNo drug interventionsprevention2completed
NCT00307567
Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjugate Vaccine or a Single Dose of 23-valent Plain Polysaccharide Vaccine in Healthy Children Aged 11-18 Mths, Previously Vaccinated in Study 103488No drug interventionsprevention2completed
NCT00654901
Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infanrix Hexa™prevention3completed
NCT00136604
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30mprevention3completed
NCT00610168
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.prevention4completed
NCT00473668
Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hibprevention3completed
NCT00932269
Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable DiseaseNo drug interventionsNot AvailableNot Availableunknown_status
NCT00254969
Immunogenicity and Safety of Pentaxim in South African Infantsprevention3completed
NCT01309646
Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccineprevention3completed
NCT05457946
Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary SeriesNo drug interventionsprevention2 / 3not_yet_recruiting
NCT00617812
Safety and Immunogenicity Study of a Liquid Pentavalent Combination VaccineNo drug interventionsprevention4completed
NCT00348881
Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy InfantsNo drug interventionsprevention3completed
NCT00282295
US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Diseaseprevention4completed
NCT00258895
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®prevention3completed
NCT00855855
Surveillance Program to Determine Product Specific Rates of Invasive Hib DiseaseNot AvailableNot Availablecompleted
NCT00385255
Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix in Adultsprevention3completed
NCT00315055
Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Scheduleprevention3completed
NCT01890850
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among InfantsNo drug interventionsNot AvailableNot Availablecompleted
NCT00870350
An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine BoosterNo drug interventionsbasic_science4unknown_status
NCT01086423
Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccineprevention3completed
NCT00258908
Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwanprevention3completed
NCT00674908
Phase IV Interchangeability Study of a Liquid Pentavalent Combination VaccineNo drug interventionsprevention4completed
NCT01457508
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separatelyprevention3completed
NCT00325143
Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis B Vaccineprevention3completed
NCT00290303
Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vaccine at Birth is at Least as Good as Tritanrix™-HepB/Hiberix™ Without Hepatitis B Vaccine at Birth, When Given to Healthy InfantsNo drug interventionsprevention3completed
NCT04099303
Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbed .prevention1completed
NCT01353703
Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) Vaccineprevention3completed
NCT00804284
Database Surveillance Safety Study of PENTACEL® VaccineNot AvailableNot Availablecompleted
NCT00376779
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Ageprevention2completed
NCT00263679
Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.No drug interventionsprevention3completed
NCT00317187
Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.prevention3completed
NCT00412854
Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTPa and Hib.prevention3completed
NCT00404651
Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infantsprevention3completed
NCT01090453
Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infantsprevention2completed
NCT00831753
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infantsprevention3completed
NCT00379977
Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Months of AgeNo drug interventionsprevention3completed
NCT01457547
Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccination Courseprevention4completed
NCT02089347
Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years Oldprevention3completed
NCT00133445
Pentavalent DTaP-Hep B-IPVNo drug interventionsprevention2completed
NCT01529645
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Yearsprevention1completed
NCT01711645
Tdap Vaccine in Post-Partum Womenprevention4completed
NCT03552445
Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate VaccineNo drug interventionsprevention4completed
NCT01453998
Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217744)prevention2completed
NCT00317161
Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Birth Dose.No drug interventionsprevention3completed
NCT00772928
Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™prevention3completed
NCT00831311
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infantsprevention2completed
NCT00797511
Immunogenicity and Safety of Adacel Polio Vaccineprevention3completed
NCT00313911
Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and 6 Months.prevention3completed
NCT01948193
Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccine at Birthprevention3completed
NCT01346293
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Ageprevention3completed
NCT00548171
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058prevention4completed
NCT02447978
Duration of Protection: GSK DTaP VaccinesNot AvailableNot Availablecompleted
NCT00970307
Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Months of Ageprevention2completed
NCT00514709
Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino Infantsprevention3completed
NCT00325156
Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Healthy Infantsprevention4completed
NCT00297856
Post-marketing Safety Study of GSK Biologicals' Boostrix® VaccineNot AvailableNot Availablecompleted
NCT04177485
Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, UgandaNo drug interventionspreventionNot Availablecompleted
NCT00908115
Post Market Surveillance for Infanrix™Not AvailableNot Availablecompleted
NCT03998215
Diphtheria Vaccination in Adolescents With Inflammatory Bowel DiseaseNo drug interventionspreventionNot Availablecompleted
NCT00259337
Immunogenicity and Safety of Pentaxim™ in an Indian Populationprevention3completed
NCT00463437
Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccinesprevention3completed
NCT01577732
Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlersprevention3completed
NCT00871000
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.prevention3completed
NCT01147900
Evaluation of Boostrix™10 Years After Previous Booster Vaccinationprevention4completed
NCT01105559
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control VaccineNo drug interventionsNot AvailableNot Availablecompleted
NCT00514059
Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio VaccineNo drug interventionsprevention4completed
NCT04075175
Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy SubjectsNo drug interventionstreatment1completed
NCT00197275
Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in InfantsNo drug interventionsprevention3completed
NCT04238975
A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adultsprevention2unknown_status
NCT00489970
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9prevention3completed
NCT00169442
Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given in Infantsprevention3completed
NCT01245049
Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Childrenprevention3completed
NCT01287949
Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEVAX) Followed by 2 Doses of a Diphtheria, Tetanus and Poliomyelitis Vaccine (REVAXIS) in Subjects of 40 Years of Age or Olderprevention3completed
NCT00362336
Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPVprevention3completed
NCT05091619
A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsorbedprevention3active_not_recruiting
NCT00148941
Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV Vaccinesprevention3completed
NCT00871117
Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine in Healthy Children 4-6 Yearsprevention3completed
NCT00254917
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippinesprevention4completed
NCT01362517
Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BNo drug interventionstreatment3completed
NCT01689324
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in Adolescentsprevention1 / 2completed
NCT05952596
A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy AdultsNo drug interventionsprevention1not_yet_recruiting
NCT00627458
Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccineprevention2completed
NCT01137435
Post Marketing Surveillance for ADACEL™ in South Koreaprevention4completed
NCT00317135
Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis B.prevention3completed
NCT01878435
Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve Childhood Immunization Coverage Rates and Timeliness in Western KenyaNo drug interventionsotherNot Availablecompleted
NCT02096263
Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy Infantsprevention3completed
NCT02813486
Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccineprevention1 / 2unknown_status
NCT03950986
Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care SystemNo drug interventionspreventionNot Availablecompleted
NCT00325130
Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combined Diphtheria, Tetanus, Pertussis Vaccine and Meningococcal Conjugate Vaccine in Adolescents (V501-025)prevention3completed
NCT00109330
A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccineprevention3completed
NCT00877357
Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination VaccineNo drug interventionsprevention4unknown_status
NCT01917357
A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and UnijectNo drug interventionsprevention3completed
NCT01439165
Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Doseprevention4completed
NCT00317174
A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects.No drug interventionsprevention2completed
NCT02587520
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjectsprevention1 / 2completed
NCT01003431
A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)prevention3withdrawn
NCT01993173
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.prevention3completed
NCT00362427
Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®prevention2completed
NCT01457560
Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vaccineprevention3completed
NCT02428491
Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birthprevention3completed
NCT00406562
Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Years of Age.prevention3completed
NCT02853929
Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers Vaccinated With Boostrix™ During Pregnancy or Immediately Post-deliveryprevention4completed
NCT01214889
Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants.prevention3completed
NCT00263692
Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and SafetyNo drug interventionsprevention2completed
NCT01106092
Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy ToddlersNo drug interventionsprevention2completed
NCT04618640
To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Children of 4-6 YearsNo drug interventionsprevention3unknown_status
NCT01983540
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccinationprevention3completed
NCT03208101
A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy AdultsNo drug interventionsprevention1completed
NCT00138268
Pilot Study Freeze and Transport Immune CellsNo drug interventionsNot AvailableNot Availablecompleted
NCT03589768
Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infantsprevention2completed
NCT00092469
Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED)prevention3completed
NCT00772369
Retrospective Survey of Safety of Fourth Dose Pentacel® in ChildrenNo drug interventionsNot AvailableNot Availablecompleted
NCT01449812
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccineprevention3completed
NCT01444781
Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Healthy Infantsprevention3completed
NCT01457495
Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantlyprevention2completed
NCT03341195
Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in PakistanNo drug interventionspreventionNot Availableunknown_status
NCT06056050
A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above)No drug interventionsprevention1recruiting
NCT02757950
A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administered During Pregnancy in a Maternal Immunization Program in Brazil.Not AvailableNot Availablecompleted
NCT00696423
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Childrenprevention3completed
NCT01437423
Regulatory Post-Marketing Surveillance Study for TETRAXIM™prevention4completed